TransMedics [TMDX] vs Abbott Laboratories [ABT] Detailed Stock Comparison
TransMedics
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: TransMedics wins in 4 metrics, Abbott Laboratories wins in 15 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | TransMedics | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 58.43 | 16.89 | Abbott Laboratories |
| Price-to-Book Ratio | 12.38 | 4.63 | Abbott Laboratories |
| Debt-to-Equity Ratio | 163.10 | 26.50 | Abbott Laboratories |
| PEG Ratio | 0.33 | 0.46 | TransMedics |
| EV/EBITDA | 40.50 | 21.02 | Abbott Laboratories |
| Profit Margin (TTM) | 13.49% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | 23.24% | 19.73% | TransMedics |
| EBITDA Margin (TTM) | 23.24% | 19.73% | TransMedics |
| Return on Equity | 28.21% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | 5.80% | 6.62% | Abbott Laboratories |
| Free Cash Flow (TTM) | $-80.94M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | -15.73% | 15.17% | Abbott Laboratories |
| Price-to-Sales Ratio (TTM) | 7.42 | 5.43 | Abbott Laboratories |
| Enterprise Value | $4.06B | $240.70B | Abbott Laboratories |
| EV/Revenue Ratio | 7.65 | 5.58 | Abbott Laboratories |
| Gross Profit Margin (TTM) | 61.38% | 56.44% | TransMedics |
| Revenue per Share (TTM) | $16 | $25 | Abbott Laboratories |
| Earnings per Share (Diluted) | $1.98 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | 2.07 | 0.70 | Abbott Laboratories |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
TransMedics vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| TransMedics | -1.52% | 1.15% | 7.91% | -8.98% | 64.76% | 71.32% |
| Abbott Laboratories | -0.63% | 0.47% | 1.16% | 0.03% | 7.11% | 17.89% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| TransMedics | -15.73% | 191.53% | 742.68% | 359.40% | 359.40% | 359.40% |
| Abbott Laboratories | 15.17% | 32.53% | 21.95% | 216.77% | 424.26% | 553.67% |
News Based Sentiment: TransMedics vs Abbott Laboratories
TransMedics
News based Sentiment: POSITIVE
TransMedics experienced a month of largely positive developments, including analyst upgrades, institutional investment, and a significant partnership, offsetting a slight downward revision in Q3 revenue projections. The company's strong long-term growth trajectory and innovative technology continue to attract investor interest, making it a compelling investment story.
Abbott Laboratories
News based Sentiment: POSITIVE
Abbott Laboratories reported strong Q2 2025 earnings and raised its full-year guidance, leading to positive analyst upgrades and increased institutional investment. While the ongoing NEC litigation presents a risk, the overall narrative is positive, suggesting continued growth and profitability for the company.
Performance & Financial Health Analysis: TransMedics vs Abbott Laboratories
| Metric | TMDX | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $4.00B | $234.39B |
| Market Cap Category | Mid cap | Mega cap |
| 10 Day Avg. Volume | 716,260 | 5,683,430 |
| 90 Day Avg. Volume | 946,893 | 5,498,563 |
| Last Close | $113.93 | $133.74 |
| 52 Week Range | $55.00 - $145.50 | $110.86 - $141.23 |
| % from 52W High | -21.70% | -5.30% |
| All-Time High | $177.37 (Aug 19, 2024) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -35.77% | -6.21% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.38% | 0.07% |
| Quarterly Earnings Growth | 1.86% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.32% |
| Operating Margin (TTM) | 0.23% | 0.20% |
| Return on Equity (TTM) | 0.28% | 0.31% |
| Debt to Equity (MRQ) | 163.10 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $9.35 | $29.05 |
| Cash per Share (MRQ) | $11.75 | $4.18 |
| Operating Cash Flow (TTM) | $115.27M | $9.04B |
| Levered Free Cash Flow (TTM) | $-7,754,500 | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | N/A | $1.69 |
Valuation & Enterprise Metrics Analysis: TransMedics vs Abbott Laboratories
| Metric | TMDX | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 58.43 | 16.89 |
| Forward P/E | 70.12 | 26.08 |
| PEG Ratio | 0.33 | 0.46 |
| Price to Sales (TTM) | 7.42 | 5.43 |
| Price to Book (MRQ) | 12.38 | 4.63 |
| Market Capitalization | ||
| Market Capitalization | $4.00B | $234.39B |
| Enterprise Value | $4.06B | $240.70B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.65 | 5.58 |
| Enterprise to EBITDA | 40.50 | 21.02 |
| Risk & Other Metrics | ||
| Beta | 2.07 | 0.70 |
| Book Value per Share (MRQ) | $9.35 | $29.05 |
Financial Statements Comparison: TransMedics vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TMDX | ABT |
|---|---|---|
| Revenue/Sales | $157.37M | $10.36B |
| Cost of Goods Sold | $60.78M | $4.47B |
| Gross Profit | $96.59M | $5.89B |
| Research & Development | $15.93M | $716.00M |
| Operating Income (EBIT) | $36.57M | $1.69B |
| EBITDA | $45.79M | $2.66B |
| Pre-Tax Income | $36.18M | $1.78B |
| Income Tax | $1.28M | $453.00M |
| Net Income (Profit) | $34.91M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TMDX | ABT |
|---|---|---|
| Cash & Equivalents | $310.14M | $6.53B |
| Total Current Assets | $505.92M | $23.15B |
| Total Current Liabilities | $55.60M | $13.00B |
| Long-Term Debt | $515.62M | $12.74B |
| Total Shareholders Equity | $266.31M | $49.06B |
| Retained Earnings | $-442.56M | $47.72B |
| Property, Plant & Equipment | $40.54M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TMDX | ABT |
|---|---|---|
| Operating Cash Flow | $354,000 | $1.42B |
| Capital Expenditures | $-27.04M | $-484.00M |
| Free Cash Flow | $-29.89M | $933.00M |
| Debt Repayment | N/A | $-1.00B |
| Common Stock Repurchase | N/A | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | TMDX | ABT |
|---|---|---|
| Shares Short | 8.39M | 18.07M |
| Short Ratio | 8.81 | 3.68 |
| Short % of Float | 0.42% | 0.01% |
| Average Daily Volume (10 Day) | 716,260 | 5,683,430 |
| Average Daily Volume (90 Day) | 946,893 | 5,498,563 |
| Shares Outstanding | 33.62M | 1.73B |
| Float Shares | 32.96M | 1.73B |
| % Held by Insiders | 0.03% | 0.01% |
| % Held by Institutions | 1.10% | 0.81% |
Dividend Analysis & Yield Comparison: TransMedics vs Abbott Laboratories
| Metric | TMDX | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | N/A | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | N/A | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |